Showing 1 - 9 results of 9 for search 'Juanita S. Lopez (22687839)', query time: 0.01s Refine Results
  1. 1
    Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  2. 2
    Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  3. 3
    Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  4. 4
    Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  5. 5
    Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  6. 6
    Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  7. 7
    Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  8. 8
    Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:
  9. 9
    Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Other Authors: “…Juanita S. Lopez (22687839)…”
    Save to List
    Saved in:

Search Tools: